Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capmatinib - Novartis Oncology

Next Previous
Drug Profile

Capmatinib - Novartis Oncology

Alternative Names: INC-280; INCB-028060; INCB-28060

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Glioblastoma; Liver cancer; Malignant melanoma
  • Phase I/II Colorectal cancer; Head and neck cancer
  • Phase I Breast cancer; Solid tumours
  • No development reported Renal cell carcinoma

Most Recent Events

  • 05 Nov 2019 Novartis Pharmaceuticals plans a phase II trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy) in January 2020 (PO) (NCT04139317)
  • 26 Sep 2019 Novartis announces intention to submit regulatory application to the US FDA for Non-small cell lung cancer in the Q4 of 2019
  • 06 Sep 2019 Capmatinib receives Breakthrough Therapy status for Non-small cell lung cancer (Metastatic disease, First-line therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top